Am J Psychiatry 163:247-256, February 2006
doi: 10.1176/appi.ajp.163.2.247
© 2006 American Psychiatric Association
Randomized, Placebo-Controlled Trial of Olanzapine as Maintenance Therapy in Patients With Bipolar I Disorder Responding to Acute Treatment With Olanzapine
Mauricio Tohen, M.D., Dr.P.H.,
Joseph R. Calabrese, M.D.,
Gary S. Sachs, M.D.,
Michael D. Banov, M.D.,
Holland C. Detke, Ph.D.,
Richard Risser, M.S.,
Robert W. Baker, M.D.,
James C.-Y. Chou, M.D., and
Charles L. Bowden, M.D.
OBJECTIVE: In a placebo-controlled, double-blind study, the authors investigated the efficacy and safety of olanzapine as monotherapy in relapse prevention in bipolar I disorder. METHOD: Patients achieving symptomatic remission from a manic or mixed episode of bipolar I disorder (Young Mania Rating Scale [YMRS] total score  12 and 21-item Hamilton Depression Rating Scale [HAM-D] score 8) at two consecutive weekly visits following 6–12 weeks of open-label acute treatment with 5–20 mg/day of olanzapine were randomly assigned to double-blind maintenance treatment with olanzapine (N=225) or placebo (N=136) for up to 48 weeks. The primary measure of efficacy was time to symptomatic relapse into any mood episode (YMRS score  15, HAM-D score 15, or hospitalization). RESULTS: Time to symptomatic relapse into any mood episode was significantly longer among patients receiving olanzapine (a median of 174 days, compared with a median of 22 days in patients receiving placebo). Times to symptomatic relapse into manic, depressive, and mixed episodes were all significantly longer among patients receiving olanzapine than among patients receiving placebo. The relapse rate was significantly lower in the olanzapine group (46.7%) than in the placebo group (80.1%). During olanzapine treatment, the most common emergent event was weight gain; during the open-label phase, patients who received olanzapine gained a mean of 3.1 kg (SD=3.4). In double-blind treatment, placebo patients lost a mean of 2.0 kg (SD=4.4) and patients who continued to take olanzapine gained an additional 1.0 kg (SD=5.2). CONCLUSIONS: Compared to placebo, olanzapine delays relapse into subsequent mood episodes in bipolar I disorder patients who responded to open-label acute treatment with olanzapine for a manic or mixed episode.
Related Article:
-
In This Issue
Am J Psychiatry 2006 163: A38.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
S Beynon, K Soares-Weiser, N Woolacott, S Duffy, and J. Geddes
Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials
J Psychopharmacol,
July 1, 2009;
23(5):
574 - 591.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. H. Perlis, J. W. Smoller, M. A.R. Ferreira, A. McQuillin, N. Bass, J. Lawrence, G. S. Sachs, V. Nimgaonkar, E. M. Scolnick, H. Gurling, et al.
A Genomewide Association Study of Response to Lithium for Prevention of Recurrence in Bipolar Disorder
Am J Psychiatry,
June 1, 2009;
166(6):
718 - 725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Goodwin and Consensus Group of the British Association for Psy
Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology
J Psychopharmacol,
June 1, 2009;
23(4):
346 - 388.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Suppes, E. Vieta, S. Liu, M. Brecher, B. Paulsson, and Trial 127 Investigators
Maintenance Treatment for Patients With Bipolar I Disorder: Results From a North American Study of Quetiapine in Combination With Lithium or Divalproex (Trial 127)
Am J Psychiatry,
April 1, 2009;
166(4):
476 - 488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Healy
Trussed in Evidence? Ambiguities at the Interface between Clinical Evidence and Clinical Practice
Transcultural Psychiatry,
March 1, 2009;
46(1):
16 - 37.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Franks, K. Macritchie, T Mahmood, and A. Young
Bouncing back: is the bipolar rebound phenomenon peculiar to lithium? A retrospective naturalistic study
J Psychopharmacol,
June 1, 2008;
22(4):
452 - 456.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. E. Pina-Garza, P. Levisohn, K. Gucuyener, M. A. Mikati, C. R. Warnock, H. S. Conklin, and J. Messenheimer
Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months
Neurology,
May 27, 2008;
70(22_Part_2):
2099 - 2108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Sachs
Bipolar Disorder Clinical Synthesis: Where Does the Evidence Lead?
Focus,
January 1, 2007;
5(1):
3 - 13.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M.A. Hirschfeld
Comment on Guideline Watch: Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2nd Edition
Focus,
January 1, 2007;
5(1):
33 - 33.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Bibliography BIPOLAR DISORDER
Focus,
January 1, 2007;
5(1):
40 - 43.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Citrome
Maintenance treatment with olanzapine reduces relapse in people with bipolar I disorder who have responded to acute olanzapine treatment.
Evid. Based Ment. Health,
August 1, 2006;
9(3):
73 - 73.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. N. Ghaemi, D. J. Hsu, M. E. Thase, S. R. Wisniewski, A. A. Nierenberg, S. Miyahara, and G. Sachs
Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants
Psychiatr Serv,
May 1, 2006;
57(5):
660 - 665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Dando and M. Tohen
Olanzapine - relapse prevention following mania
J Psychopharmacol,
March 1, 2006;
20(2_suppl):
31 - 38.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. S. E. Hellewell
A review of the evidence for the use of antipsychotics in the maintenance treatment of bipolar disorders
J Psychopharmacol,
March 1, 2006;
20(2_suppl):
39 - 45.
[Abstract]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2006
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
